LONDON, March 20, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Sangamo BioSciences Inc. (NASDAQ: SGMO), Medivation Inc. (NASDAQ: MDVN), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research report on Amgen can be accessed at http://get.Investor-Edge.com/pdf/?c=Amgen&d=20-Mar-2015&s=AMGN. On Thursday, March 19, 2015, the NASDAQ Composite ended at 4,992.38, up 0.19%, the Dow Jones Industrial Average lost 0.65%, to finish the day at 17,959.03, and the S&P 500 closed at 2,089.27, down 0.49%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 859.73, up 0.53%, with the index also advancing 5.24% in the previous three months. Register for your complimentary reports at the links given below.

On Thursday, shares in Amgen Inc. fluctuated between $166.97 and $169.22 before ending the session 1.54% higher at $169.11. The stock reported a trading volume of 3.75 million shares, above its three months average volume of 3.51 million shares. Shares of the company traded at a PE ratio of 22.36. Amgen Inc.'s shares have advanced 3.73% in the previous three trading sessions, 8.37% in the last one month and 33.60% in the past one year. The company is trading above its 50-day and 200-day moving averages of $156.19 and $144.06, respectively. Moreover, shares of Amgen Inc. have a Relative Strength Index (RSI) of 69.22. Sign up and read the free notes on AMGN at:

http://get.Investor-Edge.com/pdf/?c=Amgen&d=20-Mar-2015&s=AMGN

Exelixis Inc.'s stock advanced 3.27%, to close the day at $2.84. The stock recorded a trading volume of 1.57 million shares, below its three months average volume of 3.95 million shares. The stock oscillated between $2.73 and $2.84 during the session. Over the last three trading sessions and over the past three months, Exelixis Inc.'s shares have surged 7.58% and 113.53%, respectively. However, the stock has lost 55.63% in the previous year. The company is trading above its 50-day and 200-day moving averages. The stock's 200-day moving average of $2.46 is above its 50-day moving average of $2.28. Additionally, Exelixis Inc. has an RSI of 54.65. The complimentary notes on EXEL can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Exelixis&d=20-Mar-2015&s=EXEL

On Thursday, shares in Sangamo BioSciences Inc. recorded a trading volume of 1.18 million shares, higher than its three months average volume of 0.96 million shares. The stock ended the day at $18.54, which was 11.02% above its previous day's closing of $16.70, and registered an intraday range of $16.69 and $18.68. Sangamo BioSciences Inc.'s shares have gained 10.82% in the last one month and 20.70% in the previous three months. However, the stock has lost 22.30% in the past one year. The company is trading above its 50-day and 200-day moving averages of $15.34 and $13.59, respectively. Furthermore, shares of Sangamo BioSciences Inc. have an RSI of 52.47. Register for free on Investor-Edge and access the latest research on SGMO at:

http://get.Investor-Edge.com/pdf/?c=Sangamo%20BioSciences&d=20-Mar-2015&s=SGMO

Medivation Inc.'s stock gained 1.72%, to close Thursday's session at $134.47, after oscillating between $131.93 and $134.85. The stock recorded a trading volume of 1.06 million shares, above its three months average volume of 1.01 million shares. Over the last one month and the previous three months, Medivation Inc.'s shares have advanced 26.91% and 24.12%, respectively. Additionally, the stock has rallied 92.54% in the last one year. The company is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $111.93 is above its 200-day moving average of $97.06. Further, Medivation Inc.'s stock traded at a PE ratio of 40.26 and has an RSI of 75.97. The complete research on MDVN is available for free at:

http://get.Investor-Edge.com/pdf/?c=Medivation&d=20-Mar-2015&s=MDVN

Tekmira Pharmaceuticals Corp.'s stock finished Thursday's session 3.69% higher at $20.49. A total of 1.31 million shares were traded, which was above its three months average volume of 1.01 million shares. The stock moved between $19.15 and $20.92 during the session. Tekmira Pharmaceuticals Corp.'s shares have surged 11.12% in the previous three trading sessions and 53.83% in the last three months. However, the stock has declined 21.19% in the past one year. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $21.10 is greater than its 200-day moving average of $17.52. Tekmira Pharmaceuticals Corp.'s stock has an RSI of 51.60. Free in depth research on TKMR is available at:

http://get.Investor-Edge.com/pdf/?c=Tekmira%20Pharma&d=20-Mar-2015&s=TKMR

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge